Find a Clinical Trial

With over 70 clinical trials across the globe, Karyopharm is committed to developing novel treatment options to patients in need. Search here for ongoing clinical trials evaluating Karyopharm’s investigational medicines.

Karyopharm-Sponsored Trials Investigator-Sponsored Trials

A Study to Evaluate Safety and Efficacy of Selinexor in Combination With Ruxolitinib in Participants With Myelofibrosis

This is a global, Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of selinexor plus ruxolitinib in treatment naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1a/1b and Phase 2. The Phase 1a of the study will be dose escalation (non-randomized dose finding study) to determine the maximum tolerated dose [MTD], recommended Phase 2 dose (RP2D), and evaluate safety and preliminary efficacy and will follow a standard 3+3 design. The Phase 1b of the study will be dose expansion (non-randomized efficacy exploration) at the determined RP2D to further assess the safety and preliminary efficacy at this dose level. The Phase 2 (randomized efficacy exploration) of the study will include MF participants who are treatment naïve randomized 1:1 to receive the combination therapy of selinexor and ruxolitinib versus (vs) ruxolitinib monotherapy.
Primary Condition
Myelofibrosis
Sponsor
Karyopharm Therapeutics Inc
Status
Recruiting
Drug
Selinexor
Phase
Phase 1
Phase 2
Age Group
18 Years+
Primary Condition
Myelofibrosis

A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician’s Choice in Participants With Previously Treated Myelofibrosis

This is a Phase 2, multicenter, two-arm, open-label study to evaluate the safety and efficacy of selinexor versus treatment per physician’s choice (PC) in participants with myelofibrosis (MF) who had at least 6 months of treatment with a Janus kinase (JAK)1/2 inhibitor. Study participants will be randomized in a 1:1 ratio to either receive selinexor or physicians’ choice of treatment.
Primary Condition
Myelofibrosis
Sponsor
Karyopharm Therapeutics Inc
Status
Recruiting
Drug
Selinexor
Phase
Phase 2
Age Group
18 Years+
Primary Condition
Myelofibrosis

Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

This is a phase II, open label, prospective, single-arm study evaluating the efficacy and safety of selinexor in patients with PMF or secondary MF (PPV-MF or PET-MF) who are refractory or intolerant to ruxolitinib and/or any other experimental JAK1/2 inhibitors.
Primary Condition
Myelofibrosis
Sponsor
University of Utah
Status
Recruiting
Drug
Selinexor
Phase
Phase 2
Age Group
18 Years+
Primary Condition
Myelofibrosis